Neratinib_SDS_MedChemExpress

合集下载

硕士论文--多奈哌齐透皮贴剂的药学研究

硕士论文--多奈哌齐透皮贴剂的药学研究
关键词:多奈哌齐;经皮给药系统;促渗剂;丙烯酸酯压敏胶;药代动力学
多奈哌齐透皮给药研究
Study of Donepezil Transdermal Patch
Abstract
Donepezil(DPB)is a piperidine—based reversible acety7lcholinesterase inhibitor. Currently DPB is the most prescribed pharmacological agent for the treatment of mild to moderate Alzheimer’S disease.It also plays the important role in improving the patient’S mental state and keeping the brain active.Now the drug dosage form of DPB has tablets and capsules.Researches have showed that aizheimer’S disease is the most common cause of
研究结果表明当使用混合丙烯酸酯压敏胶作为基质时(B/C=3/I,w/w),多奈哌齐 经皮贴剂中药物浓度超过15%wt_i产生结晶,透皮贴剂能够保证长时间的给药需求, 贴剂中有关物质的生成量较少,药物的稳定性较好,但药物的体外经皮渗透速率较低, 需要加入促渗剂提高药物的经皮渗透速率。使用脂肪酸酯1和有机酸作为混合促渗剂时, 能够起到协同促渗作用,与对照组相比,可将多奈哌齐累积透过量提高2.7倍。使用最 优处方进行大鼠体内药代动力学实验,结果表明,与口服给药相比,多奈哌齐经皮给药 后,血药浓度垒少可以维持48小时以上,药物生物利用度显著提高,-、I‘均滞留时间和 半衰期也相应显著延长。

姜黄素对动脉粥样硬化家兔内皮祖细胞的影响

姜黄素对动脉粥样硬化家兔内皮祖细胞的影响

姜黄素对动脉粥样硬化家兔内皮祖细胞的影响陈骁;林以诺;张怀勤【摘要】目的观察姜黄素对动脉粥样硬化(AS)家兔血浆非对称性二甲基精氨酸(ADMA)及骨髓血内皮祖细胞(EPCs)的影响.方法 28只家兔分为3组,即对照组(喂食普通饲料)、模型组(喂食高脂饲料)和姜黄素组(喂食高脂饲料+100mg/kg·d-1姜黄素).12周后,测定血总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、ADMA水平,计算主动脉内膜斑块面积,取主动脉弓做病理切片,采用密度梯度离心法分离兔骨髓血单个核细胞(MNCs).用贴壁法测定EPCs黏附能力,改良Boyden小室法测定EPCs迁移能力及CCK-8法测定EPCs的增殖能力.结果姜黄素组较模型组内膜斑块面积减少,差异有统计学意义(P<0.05),血浆ADMA低,差异有统计学意义(P<0.05),EPCs的黏附、迁移及增殖能力亦明显强于模型组,差异有统计学意义(P<0.05,P<0.01,P<0.05).结论姜黄素能降低血脂和血浆ADMA水平,促进粥样硬化兔骨髓血EPCs活力,具有保护血管内皮和抗动脉粥样硬化作用.【期刊名称】《心脑血管病防治》【年(卷),期】2013(013)004【总页数】4页(P279-282)【关键词】动脉粥样硬化;姜黄素;非对称性二甲基精氨酸;内皮祖细胞【作者】陈骁;林以诺;张怀勤【作者单位】325000,浙江温州医科大学附属第一医院心血管内科;325000,浙江温州医科大学附属第一医院心血管内科;325000,浙江温州医科大学附属第一医院心血管内科【正文语种】中文【中图分类】R54姜黄素(curcumin)是从姜黄中提取的一种酸性酚类物质,能减轻家兔动脉粥样硬化(atherosclerosis,AS)的病变程度,可能在多个环节上影响动脉粥样硬化的发生和发展[1,2]。

非对称性二甲基精氨酸(asymmetric dimethylarginine,ADMA)为一种内源性NO合成抑制剂,Schulze F等[3]研究认为,其为冠心病(CHD)的一个独立危险因素。

【国家自然科学基金】_硫化氢_基金支持热词逐年推荐_【万方软件创新助手】_20140731

【国家自然科学基金】_硫化氢_基金支持热词逐年推荐_【万方软件创新助手】_20140731

1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106
硫化氢抑制剂 相平衡 白云岩化 疾病模型,动物 电化学行为 特发性肺纤维化 物质平衡 煤层气 热模拟 热力学 深部岩溶 海相碳酸盐岩 浓度异常 活性多肽 沉积-改造 水驱 氧化还原 氧化应激 氧化型低密度脂蛋白 氧化 气道高反应性 气道炎症 气液系统 气体水合物 正己烷 模拟实验 材料制备 机理 施万菌属 改性活性炭 措施 扣押 成因 慢性阻塞性肺疾病 慢应变速率拉伸 心脏灌流 心肌梗死 心率 心室功能,左 微量元素 应力腐蚀 巯基 实验 天然气 大鼠模型 大鼠 多硫化氢 外源性 地球化学 咪唑类离子液体 吸附等温线 吸附性能 吸附动力学 吸附
Hale Waihona Puke 空气 磷酸化的细胞外调节蛋白激酶 磷化氢 碳酸盐岩储集层 碎屑沉积岩 硫酸镁 硫酸盐还原菌 硫酸盐生物还原 硫酸盐热化学还原反应(tsr) 硫酸盐热化学还原反应 硫化锌 硫化氢扩散 硫化氢危险浓度 硫化氢分解 硫代乙酰胺 白细胞介素 甲硫醇 生物还原作用 生物脱臭 生物滴滤塔 玻璃光波导 猪场废水 物质平衡 热化学还原作用 激光扫描共焦显微镜 溶剂效应 渗流 消失波 流动模型 活性炭 沼气水合物 沼气 河北平原 氨气 氧化性应激 氢气 气藏 气相色谱法 气侵 气体分离 气体信号分子 气-液两相流 毛细管 正戊烷 正庚烷 模型 有机硫化物 数值模拟 放射性配基 性能表征 急性肺损伤 心血管效应 心肌细胞培养 心肌病

羟基喜树碱液体栓塞剂的制备及体外栓塞效果评价

羟基喜树碱液体栓塞剂的制备及体外栓塞效果评价

羟基喜树碱液体栓塞剂的制备及体外栓塞效果评价覃玲珍1, 2, 张晅1, 吴琳娜1, 张瑾1, 潘昕1*, 李革3, 吴传斌1, 2(1. 中山大学药学院, 广东广州 510006; 2. 广东省创新药物制剂工程技术研究开发中心, 广东广州 510006;3. 广州新济药业科技有限公司, 广东广州 510006)摘要: 本文制备了羟基喜树碱立方液晶液体栓塞剂并对其体外栓塞性能进行评价。

以植烷三醇为材料制备新型立方液晶液体栓塞剂, 通过三元相图的绘制筛选最优处方; 以偏光显微镜、差示扫描量热和小角衍射等手段对栓塞剂吸水后形成的立方液晶进行结构表征; 通过液相检测和X射线衍射分析研究羟基喜树碱在制剂中的存在形式; 初步评价了载药液体栓塞剂的体外溶出; 建立了体外栓塞模型评价制剂体外栓塞性能, 并考察了胶凝时间和凝胶黏附力。

结果表明, 制得的羟基喜树碱前体栓塞溶液黏度低, 适于注射, 能在水性环境中迅速形成有生物黏附性的高黏度立方液晶, 内部结构为Pn3m型; 具有较好的体外栓塞效果, 且药物在形成凝胶后结构未发生改变, 仍以闭环活性形式存在, 药物能缓释30天以上, 说明立方液晶液体栓塞剂具备用于栓塞治疗的特点, 有用于肿瘤临床治疗的潜能。

关键词: 液体栓塞剂; 立方液晶; 植烷三醇; 羟基喜树碱中图分类号: R943 文献标识码:A 文章编号: 0513-4870 (2014) 07-1069-07Preparation and in vitro embolic efficiency evaluation ofhydroxycamptothecine-loaded liquid embolic agent QIN Ling-zhen1, 2, ZHANG Xuan1, WU Lin-na1, ZHANG Jin1, PAN Xin1*, LI Ge3, WU Chuan-bin1, 2(1. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; 2. Guangdong Research Center forDrug Delivery Systems, Guangzhou 510006, China; 3. Guangzhou Neworld Pharm. CO. Ltd, Guangzhou 510006, China) Abstract: The purpose of this study is to investigate the preparation of hydroxycamptothecine (HCPT)-loaded cubic crystal liquid embolic precursor solution, and evaluate its in vitro embolic efficiency. Phytantriolwas used as cubic crystal liquid embolic material, and the optimal formulation was selected according to ternaryphase diagram. Polarized light microscopy, differential scanning calorimetry, and small angle X-ray scattering(SAXS) were used to characterize the cubic crystal structure. High performance liquid chromatography andX-ray diffraction analysis were used to investigate the lactone ring of HCPT. In vitro dissolution was preliminaryevaluated, and the simulation embolic model was constructed to evaluate the embolic efficiency of precursorsolution. Meanwhile, the gelation time and adhesion force were investigated. The results showed that HCPT-loaded precursor solution for embolization had been successfully prepared with low viscosity which wasinjectable. The precursor solution could transform into Pn3m structure liquid crystal phase gel rapidly whencontracting with excess water. The formed HPCT gel remained its lactone form as the same in precursorsolution, and expressed the good ability to block the saline flow, and HCPT could keep sustained releasing drugover 30 days. The prepared drug-loaded embolic precursor solution showed a promising potential for vascularembolization and application in clinical treatment of tumor.Key words: liquid embolic agent; liquid crystal; phytantriol; hydroxycamptothecine收稿日期: 2014-03-23; 修回日期: 2014-04-30.基金项目: 国家自然科学基金资助项目 (81173002); 广东省创新药物制剂工程技术研究开发中心资助项目 (2011B080100019).*通讯作者 Tel: 86-20-39943427, Fax: 86-20-39943115, E-mail: pxin_1385@我国是肝癌发病率最高的国家之一[1], 肝动脉化疗栓塞术 (transcatheter arterial chemoembolization, TACE) 是治疗不能手术切除中晚期肝癌的一种公认的有效治疗方法。

Gelucire-14-44-SDS-MedChemExpress

Gelucire-14-44-SDS-MedChemExpress

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Nov.-23-2018Print Date:Nov.-23-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :Gelucire 14/44Catalog No. :HY-Y1892CAS No. :121548-04-71.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:NoneFormula:N/AMolecular Weight:N/ACAS No. :121548-04-74. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Pure form-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Oil)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2018 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

Cas号110267-81-7_Amrubicin_MedBio基本简述

Cas号110267-81-7_Amrubicin_MedBio基本简述
≥98%
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12047
BGP-15
BGP-15
66611-37-8
5mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11932
Mercaptopurine (6-MP)
Mercaptopurine (6-MP)
50-44-2
25mg
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11953
TH-302
TH-302
918633-87-1
50mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED11985
Bleomycin Sulfate
Bleomycin Sulfate
9041-93-4
10mM (in 1mL DMSO)
体内研究
氨柔比星(25 mg / kg,iv)对SCLC肿瘤,Lu-24和Lu-134具有显着的抗肿瘤活性,具有T / C值(比较治疗组的平均肿瘤生长率与对照组的平均肿瘤生长率)。每天测量肿瘤)在第14天分别为17%和9%。与携带LX-1肿瘤细胞的小鼠中的氨柔比星相比,氨柔比星(25mg / kg,iv)与顺铂和伊立替康组合显着抑制肿瘤的生长。单独使用氨柔比星或与替加氟和尿嘧啶联合使用也可抑制人类癌症异种移植模型中的肿瘤生长[2]。
≥98%
品牌
货号

大鼠血浆中抗精神分裂症候选新药S_省略_体异构体的LC_MS_MS法测定_周一萌

大鼠血浆中抗精神分裂症候选新药S_省略_体异构体的LC_MS_MS法测定_周一萌

号 20101212 ) 和 SIPI5652 ( 4,内标,纯度 99.64%,批号 20101106 ) 均由本院提供,结构式见图 1 ; 甲醇和乙酸乙酯 为色谱纯。 雄性 SD 大鼠 [ 300 ~ 390 g,上海西普尔 - 必凯实验动 物公司,合格证编号 SCXK( 沪 )2008-0016]。
性强,急性毒性和不良反应小,无致突变性 [1,2]。 1 分子结构中含有一手性碳原子,根据我国手 性新药的临床要求,有必要对 1 及其立体异构体的 药理毒理及体内过程进行比较研究。根据药动学研 究结果,再综合药效及不良反应方面的结果,确定 适当的候选新药,以进行临床前系统研究及临床申 报,开发抗精神分裂症Ⅰ类新药。本研究旨在建立 一种样品处理简单、灵敏度高的 LC-MS/MS 法,拆 分及测定大鼠体内的 1 立体异构体,并应用于血药 浓度研究。 1 仪器与试药
・ 368 ・
中国医药工业杂志 Chinese Journal of Pharmaceuticals 2012, 43(5)
药品分析与质控
大鼠血浆中抗精神分裂症候选新药 SIPI6360 立体异构体的 LC-MS/MS 法测定
周一萌1,孙 杰2,石劲敏2,唐黎明2,林 梅2*,周 斌1*
(1. 中国医药工业研究总院上海医药工业研究院,上海 200040;2. 上海市食品药品检验所,上海 201203) 摘要 : 建立了液相色谱 - 串联质谱法拆分并测定大鼠血浆中 SIPI6360 的立体异构体。采用 Daicel Chiralpak IA 手性柱,以 甲醇为流动相,采用 ESI 源正离子模式、多反应监测进行定量分析。结果显示,( R) -( +) -SIPI6360 与 ( S) -(-) -SIPI6360 立体异构体分离良好,在 0.5 ~ 100 ng/ml 浓度范围内线性关系良好。方法回收率为 94.0%~ 102.8%,批内和批间 RSD 小于 5.2%和 11.4%。 关键词:SIPI6360;精神分裂症;立体异构体;液相色谱-串联质谱;测定 中图分类号:R969;O657.7+2 文献标志码:A 文章编号:1001-8255(2012)05-0368-04

【脉铂小课堂】MedBio二甲基姜黄素是一种雄激素受体降解增强剂

【脉铂小课堂】MedBio二甲基姜黄素是一种雄激素受体降解增强剂
1.608
3、ASC-J9技术资料:
体外研究
ASC-J9能够在各种人PCa细胞中以剂量依赖性方式降解fAR和AR3。 ASC-J9还可以有效抑制CWR22Rv1-fARKD细胞中的AR靶向基因。 ASC-J9(5或10μM)显着抑制所有三种PCa细胞系中DHT诱导的细胞生长。 ASC-J9通过降解C81和C4-2细胞中的fAR和异位AR3来抑制AR靶向基因和细胞生长[1]。 ASC-J9通过破坏AR和AR共调节剂之间的相互作用选择性地促进AR降解。 ASC-J9减少细胞中AR聚集的AR-112Q。 ASC-J9抑制了SBMA PC12 / AR-112Q细胞中AR-112Q的聚集[2]。
英文名称
CAS
包装
纯度
MedBio
MED12276
Zearalenone
Zearalenone
17924-92-4
5mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12173
Telmisattan
Telmisattan
144701-48-4
100mg
≥98%
品牌
货号
中文名称
英文名称
CAS
包装
纯度
MedBio
MED12241
nor-Binaltorphimine dihydrochloride
nor-Binaltorphimine dihydrochloride
113158-34-2
10mg
≥98%
品牌
货号
ቤተ መጻሕፍቲ ባይዱ中文名称
英文名称
CAS
包装
纯度
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:May-24-2017Print Date:May-24-20171. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :NeratinibCatalog No. :HY-32721CAS No. :698387-09-61.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureGHS Classification in accordance with 29 CFR 1910 (OSHA HCS)Reproductive toxicity (Category 2)2.2 GHS Label elements, including precautionary statementsPictogramSignal word WarningHazard statement(s)No data availablePrecautionary statement(s)Obtain special instructions before use.Do not handle until all safety precautions have been read and understood.Use personal protective equipment as required.IF exposed or concerned: Get medical advice/attention2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:HKI⁻272; HKI272; HKI 272Formula:C30H29ClN6O3Molecular Weight:557.04CAS No. :698387-09-64. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-20°C 3 years4°C 2 yearsIn solvent-80°C 6 months-20°C 1 monthShipping at room temperature if less than 2 weeks.7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to brown (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductiveharm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。

相关文档
最新文档